Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 30Nivolumab 11atezolizumab 8Docetaxel 8Cisplatin 7Carboplatin 7Gemcitabine 6fludarabine 5Trastuzumab 5Paclitaxel 5Ipilimumab 5Fluorouracil 5Cyclophosphamide 5spartalizumab 4cemiplimab 4avelumab 4Polymerase Chain Reaction 4Cetuximab 4Capecitabine 4Bevacizumab 4130-nm albumin-bound paclitaxel 4aldesleukin 3Taxes 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Interleukin-2 3Gene Expression Profiling 3Drug Therapy 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Medicare Part B × Head & Neck × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡